Clinical Study

Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism?

Evanthia Diamanti-Kandarakis, Sarantis Livadas, Stylianos A Kandarakis, Alexandra Margeli¹ and Ioannis Papassotiriou¹

Endocrine Section, First Department of Medicine, Medical School, Laiko General Hospital, University of Athens, 115 27 Athens, Greece and ¹Department of Clinical Biochemistry, ‘Aghia Sophia’ Children’s Hospital, 115 27 Athens, Greece

(Correspondence should be addressed to I Papassotiriou; Email: biochem@paidon-agiasofia.gr)

Abstract

Background: Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) have been considered as important mediators of vascular remodeling and plaque instability. The formation of a complex with NGAL and MMP-9 is crucial for atherotic plaque erosion and thrombus formation. In women with polycystic ovary syndrome (PCOS), the incidence of cardiovascular clinical events is not increased, despite the fact that they display a wide spectrum of risk factors. Since the instability of atherosclerotic plaque is a key factor in the clinical manifestations of risk factors. Since the instability of atherosclerotic plaque is a key factor in the clinical manifestations of risk factors. Since the instability of atherosclerotic plaque is a key factor in the clinical manifestations of risk factors. Since the instability of atherosclerotic plaque is a key factor in the clinical manifestations of risk factors.

Aim: To determine serum levels of NGAL and MMP-9/NGAL complex in women with PCOS.

Subjects and methods: PCOS subjects (40) were compared with those (40) matched for age and body mass index (BMI) controls. In each subject, fasting levels of glucose, insulin, gonadotropins, estradiol, androgens, C-reactive protein, NGAL, and MMP-9/NGAL were determined.

Results: NGAL and MMP-9/NGAL complex levels were significantly lower in the PCOS group compared with controls (30.4 ± 24.3 vs 70.7 ± 37.9 µg/l, P < 0.0001) and (31.5 ± 26.6 vs 115.1 ± 66.9 µg/l, P < 0.0001) respectively. When patients and controls were stratified according to BMI, it was shown that NGAL and MMP-9/NGAL levels were significantly lower in lean (P < 0.0002 and P < 0.0001 respectively) and overweight (P < 0.0004 and P < 0.002 respectively) PCOS subjects compared with controls.

Conclusions: These findings indicate that NGAL and MMP-9/NGAL complex, two molecules that activate atherotic plaque erosion, is in lower concentrations in PCOS subjects. The role of NGAL and MMP-9/NGAL complex needs to be further investigated, since suppression of these atheromatous molecules might have a protective role in women with PCOS.

European Journal of Endocrinology 158 525–531

Introduction

Polycystic ovarian syndrome (PCOS) constitutes the most common endocrinopathy of women of reproductive age and its prevalence in the female population worldwide ranges from 6 to 7% (1). Elegant studies have revealed that women suffering from PCOS exhibit a broad spectrum of metabolic abnormalities, predisposing them to increased cardiovascular risk such as insulin resistance, dyslipidemia, fibrinolytic aberrations, subclinical inflammation, and raised levels of markers of oxidative stress (2, 3). Moreover, studies of endothelial function in this group of patients have disclosed the initiation of atherosclerotic process as evidenced by elevated levels of vasoconstrictive peptides, increased intima-media thickness of carotid arteries, disturbed endothelium-dependent flow-mediated dilatation of the arteries and increased coronary and aortic calcifications (4–6). Taking into account that these abnormalities are encountered as early as the second decade of life in patients with PCOS (7), these subjects represent significantly higher risk to develop cardiovascular incidents, in comparison with their age- and BMI-matched peers.

Recent studies have shown that physical disruption of atherosclerotic plaque triggers thrombus formation, which may lead to myocardial infarction. In particular, gelatinase B, also known as matrix metalloproteinase-9 (MMP-9), an endopeptidase capable of degrading the molecular components of the extracellular matrix is
thought to be associated with diseases such as abdominal aortic aneurysm, atherosclerosis, and plaque rupture (8, 9). Therefore, MMP-9 is considered to be an important mediator of vascular remodeling and plaque instability (10). MMP-9 action is enhanced by neutrophil gelatinase-associated lipocalin, also known as lipocalin-2 (NGAL), a 25 kDa glycoprotein with many diverse functions, such as scavenger of bacterial products, modulator of inflammation, and apoptosis (11). The formation of a complex with NGAL and MMP-9 is crucial for atherotic plaque erosion and thrombus formation (12–14). Hemdahl et al. have shown increased expression of NGAL and co-localization with MMP-9 in atherosclerotic plaques and myocardial infarction lesions (15).

A highly atherogenic vascular environment has been recognized in women suffering from PCOS (16). However, this atherogenic milieu is not conveyed to cardiovascular incidents, evident from the available studies and every day clinical practice (17). This fact implies the presence of potential protective mechanisms in PCOS women. Since MMP-9 and NGAL are two important factors affecting plaque stability leading to the development of cardiovascular incidents, the study of these molecules appears to be justified in women with PCOS.

**Subjects and methods**

**Subjects**

Women with PCOS, to participate in the study, had to fulfill the strict National Institute of Health (NIH) criteria (chronic anovulation – six or fewer menstrual cycles per year in association with hyperandrogenemia) (18). Hyperandrogenemia was assessed as total testosterone levels above the 95th percentile of the levels detected in the group of normal menstruating women. Other androgen excess disorders (congenital adrenal hyperplasia) were excluded accordingly. A synacthen test was conducted in each woman with a basal 17-hydroxyprogesterone (17-OHP) plasma level >1.5 ng/ml. Furthermore, all subjects in the control arm had regular periods and no hirsutism/acne. Exclusion criteria for the study included age over 40 years, known cardiovascular disease, thyroid disease, neoplasms, current smoking, diabetes mellitus, hypertension (blood pressure >140/90 mmHg), renal impairment (serum creatinine >120 μmol/l). The enrolled population was clinically healthy and not suffering from any known chronic or acute disease. Oral contraceptives or other drugs that could interfere with the hormonal and metabolic studies, if administrated, were discontinued for at least 3 months before the study. The homeostasis assessment model (HOMA) assessed according to the formula, $\text{HOMA-IR} = \text{fasting insulin (mIU/ml)} \times \text{fasting glucose (mmol/l)} / 22.5$, has been used as a marker of insulin resistance (19).

The protocol was approved from the Institutional Review Committee of the 'Laiko' General University Hospital, and written informed consent was obtained from each subject before participation into the study.

**Assays**

The samples of control and PCOS subjects were collected at the same period of time between 0800 and 1000 h, after an overnight fast. All samples were obtained during the early follicular phase (day 2–4 from the first day of spontaneous bleeding episode) or any time in an anovulatory phase with progesterone levels <5 ng/ml. In this study, we used a serum separator tube and allowed samples to clot for 30 min before centrifugation for 15 min at ~1000 g. Serum was immediately stored at −20 °C until assayed for glucose (GLU), lipids, insulin, total testosterone, sex hormone-binding globulin (SHBG), free testosterone, androstenedione (Δ4A), luteinizing hormone (LH), follicle-stimulating hormone (FSH), 17-OHP, DHEAS, estradiol (E2), high-sensitivity CRP (hsCRP), NGAL and MMP-9/NGAL; repeated freeze–thaw cycles were avoided. All measurements were performed using the ChemWell Analyzer (Awareness Technology, Palm City, FL, USA), unless otherwise stated. Synacthen test was performed using Synacthen 0.25 mg/ml (Novartis Pharma SA, Rueil-Malmaison, France). Plasma fasting glucose (mg/dl) was determined by the glucose oxidase color method (Glucose LR, GOD-PAP; Linear Chemicals, Barcelona, Spain). Determinations of serum total cholesterol, high-density lipoprotein (HDL-C), and triglycerides were performed using the Siemens Advia 1650 Clinical Chemistry System (Siemens Medical Solutions, Erlangen, Germany). Cholesterol bound to low-density lipoprotein (LDL-C) was estimated by the Friedewald equation. Internal quality control of the lipids was carried out according to the laboratory manual of the Lipid Research Clinics Program. Insulin (μU/ml) was measured by a solid-phase enzyme-amplified sensitivity immunoassay test (INS-EASIA; Biosource Technologies, Nivelles, Belgium). Total testosterone (ng/dl) was measured by ELISA (testosterone enzyme immunoassay test kit, LI7603; Linear Chemicals). SHBG (nmol/l) serum levels were measured by ELISA (SHBG ELISA, MX 520 11; IBL, Hamburg, Germany). Serum E2 was measured by RIA (Immuno-metrics, London, UK). Plasma samples were analyzed for free testosterone (pg/ml) using the commercially available Coat-A-Count FT kit (Diagnostic Products, Los Angeles, CA, USA). DHEA-S (ng/ml) serum levels were measured by DSL DHEA-S RIA kit (Diagnostic Systems Laboratories, Webster, TX, USA). LH (IU/l), and FSH (IU/l) were measured using the LHsp and FSH IRMA kits from Biosource Technologies. $\Delta4A$ (ng/ml) was measured by RIA using active androstenedione-coated tube RIA kit DSL 3800 (Diagnostic Systems Laboratories). 17-OHP was

www.eje-online.org
determined by RIA kit (ICN Pharmaceuticals Inc Costa Mesa, CA, USA). The intra- and inter-assay coefficients of variation (CVs) were < 5.0% and 7.5% respectively for all the analytes.

Determination of hsCRP was performed by a fully mechanized latex particle-enhanced immunonephelometric assay on the BN ProSpec nephelometer (Dade Behring, Liederbach, Germany). The intra- and inter-assay CVs were < 6 and 7% respectively. Serum NGAL and MMP-9/NGAL levels were determined by solid-phase ELISA techniques (R&D Systems, Minneapolis, MN, USA). The intra- and inter-assay CVs for NGAL ranged between 3.1 and 4.1% and 5.6 and 7.9% respectively, and for MMP-9/NGAL between 2.3 and 4.1% and 5.1 and 7.6% respectively.

Statistical analysis

All continuous variables showed normal distribution as it was documented by the use of the Kolmogorov–Smirnov test. Data are presented as means and S.D. The two-tailed unpaired t-test was used to evaluate the differences in normally distributed variables between the two groups. The Pearson correlation coefficient was applied to assess the correlation between the variables. Statistical analysis was performed using the statistical package SPSS 13.00 version (Statistical Package for the Social Sciences, Chicago, IL, USA). Statistical significance was set at $P < 0.05$.

Results

The two groups of patients and controls were matched for age (25.4 ± 4.5 vs 27.4 ± 4.4 years, $P > 0.05$) and BMI (25.37 ± 3.8 vs 23.46 ± 2.4 kg/m², $P > 0.09$) respectively. NGAL and MMP-9/NGAL complex concentrations were significantly lower in PCOS group compared with controls (30.4 ± 24.3 vs 70.7 ± 37.9 µg/l, $P < 0.0001$) and (31.5 ± 26.6 vs 115.1 ± 66.9 µg/l, $P < 0.0001$) respectively. Androgen values, namely total testosterone (0.83 ± 0.21 vs 0.48 ± 0.18 ng/dl, $P < 0.0001$), free testosterone (2.45 ± 0.69 vs 1.67 ± 0.51 µg/ml, $P < 0.00001$), Δ4A (3.0 ± 1.21 vs 2.2 ± 0.73 ng/ml, $P < 0.002$), and DHEAS (250 ± 20.89 vs 185.6 ± 13.75 ng/ml, $P < 0.01$) were significantly higher in PCOS subjects. Lipids, E2 levels (57.6 ± 7 vs 62.31 ± 10.29 pmol/l, $P > 0.06$), and LH/FSH ratio (1.2 ± 0.14 vs 0.84 ± 0.14, $P > 0.64$) were comparable among the two groups. Insulin resistance index HOMA-IR (2.31 ± 1.01 vs 1.8 ± 0.96, $P < 0.02$) and hsCRP (3.8 ± 0.92 vs 1.78 ± 0.3 mg/l, $P < 0.05$) were significantly higher in PCOS than in controls (Table 1).

When NGAL and MMP-9/NGAL levels were stratified according to BMI status in patients and controls, namely lean with BMI ≤ 25 kg/m² and overweight with BMI > 25 kg/m², we found that NGAL levels were significantly lower in either lean ($n = 25$; 31.9 ± 5.3 vs 70.7 ± 7.5 µg/l, $P < 0.0002$) or overweight ($n = 15$; 26.7 ± 5.6 vs 72.5 ± 10.9, $P < 0.0004$) PCOS patients compared with controls (lean, $n = 30$; overweight, $n = 10$). Also, MMP-9/NGAL levels were significantly lower in lean (29.0 ± 6.6 vs 119.5 ± 12.8 µg/l, $P < 0.0001$) and overweight (37.6 ± 11.3 vs 110.7 ± 18.9, $P < 0.002$) PCOS subjects compared with controls (Fig. 1A and B). The two subgroups, lean and obese/overweight, when divided to PCOS patients and controls, have similar differences among them. Namely, they did not differ in age (24 ± 0.8 vs 25.93 ± 0.84 and 25.00 ± 1.81 vs 28.13 ± 1.1 years, in lean and overweight respectively). Also, the two subgroups were comparable for BMI (21.8 ± 0.4 vs 21.3 ± 0.4 and 31.3 ± 1.4 vs 29.3 ± 1.5 kg/m² in lean and overweight respectively). Additionally, E2 values were similar in the subgroups (60.5 ± 14.7 vs 51.14 ± 6.0 and 57.3 ± 15.3 vs 53.97 ± 11.64 pmol/l). Testosterone values were significantly higher in PCOS group in either lean (0.48 ± 0.02 vs 0.81 ± 0.05 ng/dl, $P < 0.0001$) or overweight (0.81 ± 0.05 vs 0.48 ± 0.02 ng/dl, $P < 0.0001$). Based on HOMA-IR index, PCOS overweight subgroups were more insulin resistant than controls (2.64 ± 0.33 vs 1.7 ± 0.17, $P = 0.01$), whereas lean PCOS were comparable with controls (2.03 ± 0.14 vs 1.65 ± 0.18, $P = NS$). Finally, hsCRP values were higher in PCOS than in controls in both subgroups, but this difference did not reach statistical significance in either subgroup (2.47 ± 0.77 vs 1.2 ± 0.29 mg/l and 2.47 ± 0.77 vs 1.2 ± 0.29, in lean and overweight respectively).

Considering the total number of subjects, PCOS and controls, NGAL levels were positively correlated with age ($r = 0.337, P < 0.002$) and negatively with testosterone ($r = -0.348, P < 0.002$), free testosterone ($r = -0.325$, $P < 0.005$).

### Table 1 Pertinent data in polycystic ovary syndrome (PCOS) subjects and controls.

<table>
<thead>
<tr>
<th></th>
<th>PCOS</th>
<th>Controls</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>25.4 ± 4.5</td>
<td>27.4 ± 4.4</td>
<td>0.06</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.3 ± 3.8</td>
<td>23.4 ± 2.4</td>
<td>0.09</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>184.8 ± 31.6</td>
<td>169.4 ± 33.7</td>
<td>0.12</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>90.5 ± 44.6</td>
<td>89.2 ± 56.6</td>
<td>0.93</td>
</tr>
<tr>
<td>HDL-C (mg/dl)</td>
<td>51.9 ± 9.5</td>
<td>49.0 ± 9.9</td>
<td>0.33</td>
</tr>
<tr>
<td>LDL-C (mg/dl)</td>
<td>114.8 ± 29.6</td>
<td>100.6 ± 26.1</td>
<td>0.11</td>
</tr>
<tr>
<td>E2 (pmol/l)</td>
<td>57.6 ± 7</td>
<td>62.3 ± 10.3</td>
<td>0.07</td>
</tr>
<tr>
<td>TESTO (ng/dl)</td>
<td>0.8 ± 0.21</td>
<td>0.4 ± 0.1</td>
<td>0.0001</td>
</tr>
<tr>
<td>SHBG (nmol/l)</td>
<td>38.8 ± 17.3</td>
<td>50.5 ± 21.9</td>
<td>0.01</td>
</tr>
<tr>
<td>FTESTO (pg/ml)</td>
<td>2.4 ± 0.7</td>
<td>1.67 ± 0.51</td>
<td>0.0001</td>
</tr>
<tr>
<td>17-OHDP (ng/ml)</td>
<td>1.2 ± 0.6</td>
<td>0.9 ± 0.3</td>
<td>0.06</td>
</tr>
<tr>
<td>Δ4A (ng/ml)</td>
<td>3 ± 1.2</td>
<td>2.2 ± 0.7</td>
<td>0.002</td>
</tr>
<tr>
<td>DHEAS (ng/ml)</td>
<td>250 ± 21</td>
<td>185 ± 14</td>
<td>0.01</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>2.3 ± 1</td>
<td>1.8 ± 0.9</td>
<td>0.02</td>
</tr>
<tr>
<td>hsCRP (mg/l)</td>
<td>3.8 ± 0.9</td>
<td>1.8 ± 0.3</td>
<td>0.05</td>
</tr>
<tr>
<td>NGAL (µg/l)</td>
<td>30.4 ± 24.3</td>
<td>70.7 ± 38</td>
<td>0.0001</td>
</tr>
<tr>
<td>MMP-9/NGAL (µg/l)</td>
<td>31.6 ± 26.6</td>
<td>115.1 ± 66.9</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

s.d. is presented for age, BMI, and lipids. In all other variables, the S.E.M. is presented.
MMP-9/NGAL complex was also positively correlated with age ($r = 0.451$, $P < 0.001$) and negatively correlated with testosterone ($r = -0.457$, $P < 0.001$), free testosterone ($r = -0.394$, $P < 0.002$), Δ4A ($r = -0.313$, $P < 0.02$), DHEAS values ($r = -0.324$, $P < 0.009$), and glucose values ($r = -0.227$, $P < 0.05$). Neither NGAL nor MMP-9/NGAL complex were correlated with BMI, lipids, gonadotropins, E$_2$, 17-OHP, SHBG, insulin, HOMA-IR, and hsCRP.

When PCOS and controls were studied as separate groups, a negative association was observed between NGAL and MMP-9/NGAL complex with testosterone, free testosterone, and DHEAS in PCOS, whereas age was positively correlated with both NGAL and MMP-9/NGAL complex in both groups (Table 2).

**Discussion**

In this study, it was demonstrated that serum concentrations of NGAL and MMP-9/NGAL, two well-defined factors in the evolution of atherogenic processes, were significantly lower in PCOS than those in control women (8, 14). These findings suggest that the
Table 2 Correlations of several variables among the two groups.

<table>
<thead>
<tr>
<th>PCOS</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>NGAL</td>
<td>0.791^*</td>
</tr>
<tr>
<td>MMP-9/NGAL</td>
<td>0.341^*</td>
</tr>
<tr>
<td>CRP</td>
<td>0.103</td>
</tr>
<tr>
<td>AGE</td>
<td>0.406†</td>
</tr>
<tr>
<td>TESTO</td>
<td>0.315†</td>
</tr>
<tr>
<td>D4</td>
<td>0.287</td>
</tr>
<tr>
<td>DHEAS</td>
<td>0.164</td>
</tr>
<tr>
<td>E2</td>
<td>0.065</td>
</tr>
<tr>
<td>SHBG</td>
<td>0.132</td>
</tr>
<tr>
<td>BMI</td>
<td>0.034</td>
</tr>
<tr>
<td>HOMA</td>
<td>0.103</td>
</tr>
</tbody>
</table>

Correlation is significant at the 0.05 level.

NGAL and MMP-9/NGAL in PCOS

Decreased levels of disruptors of atherosclerotic plaque may protect PCOS subjects from manifesting cardiovascular events, despite the presence of increased risk factors (20). In several studies concerning patients with PCOS, endothelial dysfunction, fibrinolytic derangements, insulin resistance, and subclinical inflammation have been detected, suggesting that these patients are at high risk of developing cardiovascular incidents (21, 22). The fact that in PCOS patients overt cardiovascular incidents are not frequently encountered indicates possible protective factors in PCOS subjects that delay or inhibit atherogenic process.

MMP-9 is a proteolytic enzyme participating in the remodeling of extracellular matrix. An increased activity of MMP-9 has been reported in atherosclerosis and cardiovascular disease (23). NGAL or lipocalin 2 is thought to be an acute phase protein whose expression is up-regulated in humans, typically in epithelial cells, under diverse inflammatory conditions (24). Additionally, a role of NGAL as a mediator of insulin resistance has been recently suggested (25, 26). Overall, the full functional repertoire of NGAL remains to be elucidated.

Of particular interest is the finding that NGAL inhibits MMP-9 inactivation, leading to enhanced proteolytic activity with prolonged effects on collagen degradation (27). Indeed, Hemdal et al. have found increased expression and co-localization of MMP-9 and NGAL in atherosclerotic lesions, especially in myocardial infarction (15).

Considering the fact that NGAL and MMP-9 are clearly involved in the final steps of vascular damage, their decreased concentrations in PCOS subjects indicate that they might be part of a protective mechanism. In the present study, the significantly lower concentrations of NGAL and MMP-9/NGAL complex appear to be independent of the degree of obesity. Low concentrations of NGAL and MMP-9/NGAL complex cannot be attributed to estrogen levels, since they were similar among patients and controls. The negative association of these atherogenic molecules with androgens advocates a probable role of androgens in cardiovascular protection in PCOS subjects. The role of androgens in cardiovascular risk factors in women with PCOS has been controversial; however, there are studies suggesting a protective role of androgens (28, 29). Interestingly, no association of NGAL and MMP-9/NGAL complex with insulin resistance or hsCRP was demonstrated in this study, a finding that implies alternative pathways of NGAL and MMP-9 regulation.

To our knowledge, this is the first study addressing NGAL and MMP-9/NGAL complex in PCOS subjects. Lewandowski et al. have studied MMP-9 concentration in PCOS and they have detected elevated values in PCOS women (30). However, their studied group of PCOS consisted of significantly heavier and older women than in the present study (BMI 35.8 ± 7.5 vs 25.4 ± 3.8 kg/m², age 30.5 ± 6.7 vs 25.4 ± 4.5 years).
These parameters affect the final outcome since in both studies, MMP-9 and NGAL/MMP-9 complex were positively related to age, and in the study of Lewandowski et al. there was a positive association between MMP-9 and BMI. Noticeably, NGAL and MMP-9/NGAL complex is a more sensitive marker of atherogenic risk in humans than solely MMP-9, since these two factors taken together act in cooperation leading to plaque erosion and consequently the evolution of cardiovascular events.

In conclusion, the presented data indicate that NGAL and MMP-9/NGAL complex, two molecules activating the erosion of atherotic plaque, are lower in PCOS subjects. These findings could contribute in elucidating the discrepancy between the increased estimated prevalence as opposed to lower clinically confirmed incidence of cardiovascular events in women with PCOS.

Acknowledgements

Grant/funding support: funding was received from the Athens University Medical School (to E D-K). The funding source played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

2 Duniaf A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews 1997 18 774–800.
4 Diamanti-Kandarakis E, Alexandraki K, Protergouros A, Picieli C, Papamichael C, Aessopos A, Lekakis I & Mavrikakis M. Metformin administration improves endothelial function in women with polycystic ovary syndrome. European Journal of Endocrinology 2005 152 749–756.
7 Coviello AD, Legro RS & Duniaf A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. Journal of Clinical Endocrinology and Metabolism 2006 91 492–497.


Received 21 December 2007

Accepted 2 January 2008